ConvaTec (2CV) Stock Price & Analysis
2CV Stock Chart & Stats
- Day’s Range
- CHF 2.68 - CHF 2.72
- 52-Week Range
- CHF 2.28 - CHF 2.73
- Previous Close
- CHF 2.66
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- CHF 5.16B
- Enterprise Value
- CHF 5.45B
- Total Cash (Recent Filing)
- CHF 99.51M
- Total Debt (Recent Filing)
- CHF 1.75B
- Price to Earnings (P/E)
- 51.6
- Beta
- 1.10
- Next Earnings
- Feb 23, 2027 (Est.)
- EPS Estimate
- 0.1
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.19%
Bulls Say, Bears Say
Bulls Say
Recurring Consumables Model
ConvaTec sells consumables that patients and healthcare providers must replenish regularly, creating recurring demand across ostomy, wound, continence and infusion care. This replacement-driven model can support durable revenue visibility and resilience across healthcare settings over the next several quarters.
Revenue And Margin Improvement
Steady revenue growth alongside meaningful operating-margin expansion indicates improving operating execution and cost control. A stronger profit engine can support investment in innovation and capacity while increasing the company’s ability to absorb category-specific softness over the medium term.
Infusion And Product Pipeline Momentum
Infusion Care is providing a growth vector supported by diabetes demand and strong expansion outside diabetes, while new products are progressing through launch phases. Continued category momentum and innovation may broaden growth and strengthen ConvaTec’s position in chronic-care consumables.
Bears Say
Higher Leverage
The increase in debt relative to equity reduces financial flexibility and makes results more sensitive to earnings pressure or financing costs. Higher leverage may constrain capital allocation choices and leave less capacity to fund growth or absorb operational setbacks.
InnovaMatrix Deterioration
The sharp InnovaMatrix sales collapse and impairment demonstrate that part of the portfolio has suffered a substantial commercial setback. Although management expects the product to become small, the decline has reduced growth, damaged margins and weakened confidence in near-term earnings quality.
Multi-year FDA Remediation
A remediation program extending through 2027 creates an ongoing execution burden and keeps regulatory compliance as a durable management priority. Even without current product-safety or manufacturing disruption, prolonged remediation can consume resources and introduce operational uncertainty.
ConvaTec News
2CV FAQ
What was ConvaTec’s price range in the past 12 months?
What is ConvaTec’s market cap?
When is ConvaTec’s upcoming earnings report date?
How were ConvaTec’s earnings last quarter?
Is ConvaTec overvalued?
Does ConvaTec pay dividends?
What is ConvaTec’s EPS estimate?
How many shares outstanding does ConvaTec have?
What happened to ConvaTec’s price movement after its last earnings report?
Which hedge fund is a major shareholder of ConvaTec?
What is the TipRanks Smart Score and how is it calculated?
ConvaTec Stock Smart Score
Company Description
ConvaTec
ConvaTec Group Plc operates as a global medical technology company, specializing in the creation, production, and worldwide distribution of a diverse array of healthcare products. Its offerings span critical areas, including advanced wound care, where it provides specialized dressings and skin care items for managing acute and chronic wounds that arise from conditions like diabetes, immobility, venous disease, traumatic injuries, burns, or surgical recovery. The company is also a key provider in ostomy care, delivering essential devices, accessories, and support services for individuals living with a stoma due to conditions such as colorectal cancer, inflammatory bowel disease, bladder cancer, and obesity. Beyond wound and ostomy solutions, ConvaTec's portfolio extends to continence and critical care. This includes intermittent urinary catheters and related products designed to assist individuals with urinary continence issues stemming from spinal cord injuries, multiple sclerosis, spina bifida, and other urological disorders. They also furnish equipment for intensive care units and hospital settings, alongside advanced systems for managing acute fecal incontinence and monitoring urine output and intra-abdominal pressure. Additionally, ConvaTec supplies various disposable medical devices, such as wound drainage systems, urine collection bags, airway management tools, gastroenterology tubes, and securement devices. The company manufactures disposable infusion sets for insulin pumps used in diabetes treatment, as well as for other continuous infusion therapies. These products reach pharmacies, hospitals, and both acute and post-acute healthcare providers directly, or through a network of distributors and wholesalers, catering to healthcare professionals, patients, and other manufacturers. Established in 1978, ConvaTec Group Plc is headquartered in Reading, United Kingdom.
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- CEO
- Jonathan Peter Mason
- Employees
- 10,910
- Website
- www.convatecgroup.com
- Address
- 20 Eastbourne Terrace, London, GL, W2 6LG, GB
ConvaTec (2CV) Earnings & Revenues
2CV Earnings Call
Earnings Call SentimentPositive
The call conveyed an upbeat, constructive tone: management confirmed they are on track for FY '26 targets (revenue growth, at least 23% operating margin, and continued double‑digit EPS growth), announced a USD 200m buyback and highlighted robust Infusion Care momentum, multiple product launches with strong clinical evidence (notably ConvaNiox) and clear CapEx to support long-term growth. Key challenges include the disappointing InnovaMatrix performance and impairment, softer wound care trading in parts of H1, H1 cash timing pressures, currency headwinds and a multi-year FDA remediation program. On balance, the positive execution on strategy, operational productivity, financing actions and high-confidence Infusion Care order visibility outweigh the near-term setbacks.
View all CH:2CV earnings summaries2CV Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 11 | 4 | 3 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 8 | 0 | 0 |